Peroxiredoxin I expression in oral cancer: A potential new tumor marker

Cancer Letters

Volumn 156, Issue 1, 2000, Pages 27-35

  Yanagawa, Toru ^a   Iwasa, Satoshi ^b   Ishii, Tetsuro ^b   Tabuchi, Katsuhiko ^c   Yusa, Hiroshi ^a   Onizawa, Kojiro ^a   Omura, Ken ^d   Harada, Hiroyuki ^d   Suzuki, Haruhiko ^d   Yoshida, Hiroshi ^a  

^a Univ T   (Japan)

^b UNIVERSITY OF TSUKUBA   (Japan)

^c HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^d CHIBA CANCER CENTER   (Japan)

Author keywords

MSP23; Natural killer enhancing factor; Peroxiredoxin; Proliferating cell nuclear antigen; Proliferation associated gene; Squamous cell carcinoma

Indexed keywords

CYCLINE; PEROXIREDOXIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOHISTOLOGY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MOUTH CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MOUTH NEOPLASMS; NEOPLASM STAGING; PEROXIDASES; PROLIFERATING CELL NUCLEAR ANTIGEN; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 18744426119     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(00)00434-1     Document Type: Article

References (37)

1. Aaltomaa S., Lipponen P., Syrjanen K. Prognostic value of cell proliferation in breast cancer as determined by proliferating cell nuclear antigen (PCNA) immunostaining. Anticancer Res. 12:1992;1281-1286.
2. al Sheneber I.F., Shibata H.R., Sampalis J., Jothy S. Prognostic significance of proliferating cell nuclear antigen expression in colorectal cancer. Cancer. 71:1993;1954-1959.
3. Derenzini M., Trere D. AgNOR proteins as a parameter of the rapidity of cell proliferation. Zentralbl Pathol. 140:1994;7-10.
4. Hofstadter F., Knuchel R., Ruschoff J. Cell proliferation assessment in oncology. Virchows Arch. 427:1995;323-341.
5. Elias J.M. Cell proliferation indexes: a biomarker in solid tumors. Biotech.-Histochem. 72:1997;78-85.
6. Prosperi M.T., Ferbus D., Karczinski I., Goubin G. A human cDNA corresponding to a gene overexpressed during cell proliferation encodes a product sharing homology with amoebic and bacterial proteins. J. Biol. Chem. 268:1993;11050-11056.
7. Wen S.T., Vanetten R.A. The pag gene product, a stress-induced protein with antioxidant properties, is an abl SH3-binding protein and a physiological inhibitor of c-Abl tyrosine kinase activity. Genes Dev. 11:1997;2456-2467.
8. Yamamoto T., Matsui Y., Natori S., Obinata M. Cloning of a housekeeping-type gene (MER5) preferentially expressed in murine erythroleukemia cells. Gene. 80:1989;337-343.
9. Ishii T., Yamada M., Sato H., Matsue M., Taketani S., Nakayama K., Sugita Y., Bannai S. Cloning and characterization of a 23-kDa stress-induced mouse peritoneal macrophage protein. J. Biol. Chem. 268:1993;3-18636.
10. Shau H., Butterfield L.H., Chiu R., Kim A. Cloning and sequence analysis of candidate human natural killer-enhancing factor genes. Immunogenetics. 40:1994;129-134.
11. Iwahara S., Satoh H., Song D.X., Webb J., Burlingame A.L., Nagae Y., Muller Eberhard U. Purification, characterization, and cloning of a heme-binding protein (23 kDa) in rat liver cytosol. Biochemistry. 34:1995;13398-13406.
12. Kang S., Chae H., Seo M., Kim K., Baines I., Rhee S. Mammalian peroxiredoxin isoforms can reduce hydrogen peroxidegenerated in response to growth factors and tumor necrosis factor-alpha. J. Biol. Chem. 273:1998;6297-6302.
13. Lim M.J., Chae H.Z., Rhee S.G., Yu D.Y., Lee K.K., Yeom Y.I. The type II peroxiredoxin gene family of the mouse: molecular structure, expression and evolution. Gene. 216:1998;197-205.
14. Kim A.T., Sarafian T.A., Shau H. Characterization of antioxidant properties of natural killer-enhancing factor-B and induction of its expression by hydrogen peroxide. Toxicol. Appl. Pharmacol. 147:1997;135-142.
15. Goodwin W.J. Jr., Lane H.W., Bradford K., Marshall M.V., Griffin A.C., Geopfert H., Jesse R.H. Selenium and glutathione peroxidase levels in patients with epidermoid carcinoma of the oral cavity and oropharynx. Cancer. 51:1983;110-115.
16. Mulder T.P., Manni J.J., Roelofs H.M., Peters W.H., Wiersma A. Glutathione peroxidases in human head and neck cancer. Acta Otolaryngol. (Stockholm). 115:1995;331-333.
17. Rubartelli A., Bonifaci N., Sitia R. High rates of thioredoxin secretion correlate with growth arrest in hepatoma cells. Cancer Res. 55:1995;675-680.
18. Wakita H., Yodoi J., Masutani H., Toda K., Takigawa M. Immunohistochemical distribution of adult T-cell leukemia-derived factor/thioredoxin in epithelial components of normal and pathologic human skin conditions. J. Invest. Dermatol. 99:1992;101-107.
19. Seidman M.D., Quirk W.S., Shirwany N.A. Reactive oxygen metabolites, antioxidants and head and neck cancer. Head Neck. 21:1999;467-479.
20. Sobin L.H., Wittekind Ch. TNM Classification of Malignant Tumor, 5th fully revised edition. 1997;Wiley-Liss, New York.
21. Ishii T., Kawane T., Taketani S., Bannai S. Inhibition of the thiol-specific antioxidant activity of rat liver MSP23 protein by hemin. Biochem. Biophys. Res. Commun. 216:1995;970-975.
22. Yanagawa T., Ishikawa T., Ishii T., Tabuichi K., Iwasa S., Bannai S., Omura K., Suzuki H., Yoshida H. Peroxiredoxin I expression in human tyroid tumors. Cancer Lett. 145:1999;127-132.
23. Johnston P., Fisher E., Rockette H., Fisher B., Wolmark N., Drake J., Chabner B., Allegra C. The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J. Clin. Oncol. 12:1994;2640-2647.
24. Willen R., Nathanson A., Moberger G., Anneroth G. Squamous cell carcinoma of the gingiva Histological classification and grading of malignancy. Acta Oto. Laryngol. 79:1975;146-154.
25. Prosperi M.T., Ferbus D., Rouillard D., Goubin G. The pag gene product, a physiological inhibitor of c-abl tyrosine kinase, is overexpressed in cells entering S phase and by contact with agents inducing oxidative stress. FEBS Lett. 423:1998;39-44.
26. Fontanini G., Macchiarini P., Pepe S., Ruggiero A., Hardin M., Bigini D., Vignati S., Pingitore R., Angeletti C.A. The expression of proliferating cell nuclear antigen in paraffin sections of peripheral, node-negative non-small cell lung cancer. Cancer. 70:1992;1520-1527.
27. Bravo R., Frank R., Blundell P.A., Macdonald Bravo H. Cyclin/PCNA is the auxiliary protein of DNA polymerase-delt. Nature. 326:1987;515-517.
28. Tron V.A., Tang L., Yong W.P., Trotter M.J. Differentiation-associated overexpression of the cyclin-dependent kinase inhibitor p21waf-1 in human cutaneous squamous cell carcinoma. Am. J. Pathol. 149:1996;1139-1146.
29. Zhang P., Liu B., Kang S.W., Seo M.S., Rhee S.G., Obeid L.M. Thioredoxin Peroxidase is a novel inhibitor of apoptosis with a mechanism distinct from that of Bcl-2. J. Biol. Chem. 272:1997;30615-30618.
30. Wen S.T., Jackson P.K., Van Etten R.A. The cytostatic function of c-Abl is controlled by multiple nuclear localization signals and requires the p53 and Rb tumor suppressor gene products. EMBO J. 15:1996;1583-1595.
31. Felix A., El-Naggar A.K., Press M.F., Ordonez N.G., Fonseca I., Tucker S.L., Luna M.A., Batsakis J.G. Prognostic significance of biomarkers (c-erbB-2, p53, proliferating cell nuclear antigen, and DNA content) in salivary duct carcinoma. Hum. Pathol. 27:1996;561-566.
32. El-Naggar A.K., Lai S., Clayman G.L., Zhou J.H., Tucker S.A., Myers J., Luna M.A., Benedict W.F. Expression of p16 Rb, and cyclin D1 gene products in oral and laryngeal squamous carcinoma: biological and clinical. Hum. Pathol. 30:1999;1013-1018.
33. Pande P., Mathur M., Shukla N.K., Ralhan R. pRb and p16 protein alterations in human oral tumorigenesis. Oral Oncol. 34:1998;396-403.
34. Brennan J.A., Mao L., Hruban R.H., Boyle J.O., Eby Y.J., Koch W.M., Goodman S.N., Sidransky D. Molecular assessment of histopathological staging in squamous-cell carcinoma of the head and. N. Engl. J. Med. 332:1995;429-435.
35. Boyle J.O., Hakim J., Roch W., van der Riet P., Hruban R.H., Roa R.A., Correo R., Eby Y.J., Ruppert J.M., Sidransky D. The incidence of p53 mutations increases with progression of head and neck cancer. Cancer Res. 53:1993;4477-4480.
36. Kuo M.Y., Lin C.Y., Hahn L.J., Cheng S.J., Chiang C.P. Expression of cyclin D1 is correlated with poor prognosis in patients with areca quid chewing-related oral squamous cell carcinomas in Taiwan. J. Oral Pathol. Med. 28:1999;165-169.
37. Pavelic Z.P., Lasmar M., Pavelic L., Sorensen C., Stambrook P.J., Zimmermann N., Gluckman J.L. Absence of retinoblastoma gene product in human primary oral cavity carcinomas. Oral Oncol. 32:1996;347-351.